Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Taladegib
Synonyms
Therapy Description

Taladegib inhibits the Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (PMID: 22007748, Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1: Abstract #2819).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Taladegib LY2940680|LY-2940680 SMO Inhibitor 16 Taladegib (LY-2940680) inhibits the Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (PMID: 22007748, Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1: Abstract #2819, PMID: 29483143, PMID: 29453627).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO wild-type medulloblastoma sensitive Taladegib Preclinical Actionable In a preclinical study, LY2940680 was demonstrated to bind to the Smo receptor and inhibit hedgehog signaling in a human medulloblastoma tumor cell line (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819). detail...
SMO T241M Advanced Solid Tumor decreased response Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
SMO W281C Advanced Solid Tumor decreased response Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
SMO V321M Advanced Solid Tumor decreased response Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
SMO A459V Advanced Solid Tumor decreased response Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
SMO I408V Advanced Solid Tumor decreased response Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
SMO D473H Advanced Solid Tumor sensitive Taladegib Preclinical Actionable In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819). detail...
SMO C469Y Advanced Solid Tumor decreased response Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
Unknown unknown basal cell carcinoma not applicable Taladegib Phase I Actionable In a Phase I trial, Taladegib treatment resulted in a clinical response in 46.8% (22/47) of patients with basal cell carcinoma, including 16 patients with a confirmed partial response, 1 patient with an unconfirmed partial response, and 5 patients with a confirmed complete response (PMID: 29483143). 29483143

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02530437 Phase Ib/II Taladegib Carboplatin + Paclitaxel A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction Active, not recruiting USA 0
NCT01722292 Phase Ib/II Taladegib Carboplatin + Etoposide A Study of LY2940680 in Small Cell Lung Cancer Terminated USA 1


Additional content available in CKB BOOST